Literature DB >> 12090560

Revisiting the anticardiolipin test and its standardization.

E N Harris1, S S Pierangeli.   

Abstract

Although the importance of the anticardiolipin test in diagnosis of antiphospholipid syndrome (APS) is widely accepted, there remains much misunderstanding about the strengths and weaknesses of this assay. Several disorders result in formation of low levels of the antibody, hence the anticardiolipin test is not specific when results are low positive. In general, the higher the anticardiolipin level the greater the likelihood of a diagnosis of APS. Hence there have been numerous efforts to enable reproducible measurement of anticardiolipin levels. Standard calibrators were introduced to construct calibration curves from which levels of unknown samples can be derived. Those standard calibrators were made by mixing varying quantities of high positive with normal sera. More recently, calibrators derived from monoclonal anticardiolipin antibodies have been introduced. There are advantages and disadvantages with both types of calibrators. Determination of a precise and reproducible anticardiolipin level is difficult, whatever the calibrators used, because the assay is dependent on several variable components, any of which may fail on any given day. Utilization of a semi-quantitative measure (low, medium, high) may suffice in most clinical settings and would be less subject to error. Validated ELISA kits may offer greater reproducibility, since there is less variability than bench assays set up in very different laboratories. Whether using a kit or a bench assay, meticulous attention to detail offers the best opportunity for precision and reproducibility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090560     DOI: 10.1191/0961203302lu202cr

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma.

Authors:  W Miesbach; I Scharrer; R A Asherson
Journal:  Clin Rheumatol       Date:  2006-05-24       Impact factor: 2.980

2.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

Review 3.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

Review 4.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

5.  Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.

Authors:  Carole Ferraro-Peyret; Fabienne Coury; Jacques G Tebib; Jacques Bienvenu; Nicole Fabien
Journal:  Arthritis Res Ther       Date:  2004-09-23       Impact factor: 5.156

6.  Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.

Authors:  Kathryn A K Finton; Kevin Larimore; H Benjamin Larman; Della Friend; Colin Correnti; Peter B Rupert; Stephen J Elledge; Philip D Greenberg; Roland K Strong
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

7.  LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Carmen Manzano; Asier Fullaondo; Irama Villar; Guillermo Ruiz-Irastorza; Ana M Zubiaga; Andone Estonba
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

8.  The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies.

Authors:  Jiansuo Zhou; Xiuzhu Hou; Hua Zhang; Tiancheng Wang; Liyan Cui
Journal:  Med Sci Monit       Date:  2018-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.